The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
An anti-human interleukin 5 receptor (hIL-5R) humanized immunoglobulin G1 (IgG1) and an anti-CD20 chimeric IgG1 produced by rat hybridoma YB2/0 cell lines showed more than 50-fold higher antibody-dependent cellular cytotoxicity (ADCC) using purified human peripheral blood mononuclear cells as effector than those produced by Chinese hamster ovary (CHO) cell lines. Monosaccharide composition and oligosaccharide profiling analysis showed that low fucose (Fuc) content of complex-type oligosaccharides was characteristic in YB2/0-produced IgG1s compared with high Fuc content of CHO-produced IgG1s. YB2/0-produced anti-hIL-5R IgG1 was subjected to Lens culinaris aggulutin affinity column and fractionated based on the contents of Fuc. The lower Fuc IgG1 had higher ADCC than the IgG1 before separation. In contrast, the content of bisecting GlcNAc of the IgG1 affected ADCC much less than that of Fuc. In addition, the correlation between Gal and ADCC was not observed. When the combined effect of Fuc and bisecting GlcNAc was examined in anti-CD20 IgG1, only a severalfold increase of ADCC was observed by the addition of GlcNAc to highly fucosylated IgG1. Quantitative PCR analysis indicated that YB2/0 cells had lower expression level of FUT8 mRNA, which codes alpha1,6-fucosyltransferase, than CHO cells. Overexpression of FUT8 mRNA in YB2/0 cells led to an increase of fucosylated oligosaccharides and decrease of ADCC of the IgG1. These results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is ideal as increases in fucosylation have been correlated with decreased ADCC activity and decreased FcγRIIIa and FcγRIIb binding affinity. 40 , 41 , 42 , 43”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“lower cell specific productivity has been shown to allow for more mature glycoforms, including G2F. 42”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“Enriching the abundance of mAb N-glycoforms with β1,4-linked galactose (Gal) can also be desirable as it has been shown to enhance complement-dependent cytotoxicity (CDC), another mechanism for the selective depletion of tumour cells by Fc activation of the complement pathway [16–21].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“The addition of bisecting β1,4-linked N-acetylglucosamine (GlcNAc) by endogenous or recombinant N-acetylglucosaminyltransferase III (GnT-III in YB2/0 and CHO cells respectively) or via in vitro glycan remodelling has also been linked to increased ADCC in IgGs, albeit to a lesser extent than afucosylation [15–17].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“It was reported that afucosylated Fc domain glycans of human IgG1 could enhance the binding to FcγRIIIa subtype receptors of natural killer cells (Shields et al., 2002;Shinkawa et al., 2003;Niwa et al., 2005;Iida et al., 2006;Subedi and Barb, 2016).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Shinkawa et al., 2003
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Refined Structure of an Intact IgG2a Monoclonal Antibody,
Harris, L. J., Larson, S. B., Hasel, K. W., & McPherson, A. (1997) · Biochemistry · doi:10.1021/bi962514+ · Cited by 451
Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson
Harris, L. J., Skaletsky, E., & McPherson, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1508 · Cited by 440
Research works printed but not linked: 2
- Rademacher, 1986, Biochem. Soc. Symp., 51, 131
- Kumpel, 1994, Hum. Antib. Hybrid., 5, 143
Cited by
Items 301–400 of 1,000
Schuster, M., Umana, P., Ferrara, C., Brünker, P., Gerdes, C., Waxenecker, G., Wiederkum, S., Schwager, C., Loibner, H., Himmler, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4212 · Cited by 91
“A reason for this effect could be the presence of a bisecting-GlcNAc group which inhibits several subsequent glycosylation steps ( 32 ).”
BackgroundSibéril, S., de Romeuf, C., Bihoreau, N., Fernandez, N., Meterreau, J.-L., Regenman, A., Nony, E., Gaucher, C., Glacet, A., Jorieux, S., et al. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.10.008 · Cited by 99
Hermine, O., Ramos, J. C., & Tobinai, K. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0658-4 · Cited by 90
“It demonstrates potent antitumor activity and is mediated by highly enhanced antibody-dependent cellular cytotoxicity (ADCC) [70] because of its reduced fucose content [71].”
BackgroundModel-based optimization of antibody galactosylation in CHO cell culture
Kotidis, P., Jedrzejewski, P., Sou, S. N., Sellick, C., Polizzi, K., del Val, I. J., & Kontoravdi, C. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26960 · Cited by 90
Antibody glycosylation in autoimmune diseases
Zhou, X., Motta, F., Selmi, C. F., Ridgway, W. M., Gershwin, M. E., & Zhang, W. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102804 · Cited by 100
Sack, M., Paetz, A., Kunert, R., Bomble, M., Hesse, F., Stiegler, G. M., Fischer, R., Katinger, H. W. D., Stoeger, E., & Rademacher, T. (2007) · The FASEB Journal · doi:10.1096/fj.06-5863com · Cited by 103
“In particular, it has been shown that antibody-dependent cellular cytotoxicity is significantly increased for antibodies lacking core- (1,6)-fucose and, to a lesser extent, containing a bisecting GlcNAc (7).”
BackgroundMoss bioreactors producing improved biopharmaceuticals
Decker, E. L., & Reski, R. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.07.012 · Cited by 92
Structural analysis of Fc/FcγR complexes: a blueprint for antibody design
Caaveiro, J. M. M., Kiyoshi, M., & Tsumoto, K. (2015) · Immunological Reviews · doi:10.1111/imr.12365 · Cited by 103
“This phenomenon is specifically observed when fucose is absent, and not when other sugars such as Gal (either at the 1,6- or the 1,3-arm) or bisecting GlcNAc are present (69).”
BackgroundShatz, W., Chung, S., Li, B., Marshall, B., Tejada, M., Phung, W., Sandoval, W., Kelley, R. F., & Scheer, J. M. (2013) · mAbs · doi:10.4161/mabs.26307 · Cited by 88
Design of humanized antibodies: From anti-Tac to Zenapax
Tsurushita, N., Hinton, P. R., & Kumar, S. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.007 · Cited by 92
Profiling analysis of oligosaccharides in antibody pharmaceuticals by capillary electrophoresis
Kamoda, S., Nomura, C., Kinoshita, M., Nishiura, S., Ishikawa, R., Kakehi, K., Kawasaki, N., & Hayakawa, T. (2004) · Journal of Chromatography A · doi:10.1016/s0021-9673(04)01399-8 · Cited by 86
Sakae, Y., Satoh, T., Yagi, H., Yanaka, S., Yamaguchi, T., Isoda, Y., Iida, S., Okamoto, Y., & Kato, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-13845-8 · Cited by 94
Glycosylation Alterations in Lung and Brain Cancer
Lemjabbar‐Alaoui, H., McKinney, A., Yang, Y., Tran, V. M., & Phillips, J. J. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2014.11.007 · Cited by 102
“…determinant of antibody-dependent cell-mediated cytotoxicity, as deletion of the core fucose from the Fc region of IgG1, enhances its binding affinity to Fcγ receptor, and greatly improves (over 50 fold) antibody-dependent cell-mediated cytotoxicity (Okazaki et al., 2004; Shinkawa et al., 2003).”
BackgroundExpression and enzyme activity of α(1,6)fucosyltransferase in human colorectal cancer
Muinelo‐Romay, L., Vázquez-Martín, C., Villar‐Portela, S., Cuevas, E., Gil‐Martín, E., & Fernández‐Briera, A. (2008) · International Journal of Cancer · doi:10.1002/ijc.23521 · Cited by 95
The GalNAc-type O-Glycoproteome of CHO Cells Characterized by the SimpleCell Strategy
Yang, Z., Halim, A., Narimatsu, Y., Jitendra Joshi, H., Steentoft, C., Gram Schjoldager, K. T.-B., Alder Schulz, M., Sealover, N. R., Kayser, K. J., Paul Bennett, E., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.041541 · Cited by 84
“apeutics and effector functions of IgGs, respectively (28, 29).”
BackgroundSweet but dangerous – the role of immunoglobulin G glycosylation in autoimmunity and inflammation
Biermann, M. H. C., Griffante, G., Podolska, M. J., Boeltz, S., Stürmer, J., Munoz, L. E., Bilyy, R. O., & i, M. H. (2016) · Lupus · doi:10.1177/0961203316640368 · Cited by 97
Wang, X., Gu, J., Miyoshi, E., Honke, K., & Taniguchi, N. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(06)17002-0 · Cited by 86
Wagner‐Rousset, E., Bednarczyk, A., Bussat, M., Colas, O., Corvaïa, N., Schaeffer‐Reiss, C., DORSSELAER, A. V., & Beck, A. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.03.032 · Cited by 89
Cartron, G., Trappe, R. U., Solal‐Céligny, P., & Hallek, M. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1292 · Cited by 86
Impact of Differential Glycosylation on IgG Activity
Lux, A., & Nimmerjahn, F. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-5632-3_10 · Cited by 91
“Shinkawa and colleagues compared the effects of either enhanced levels of GlcNAcs or the lack of fucose, and found that compared to the more than 50-fold ADCC enhancement seen for IgG without fucose, the enhancement of activity for IgG with high levels of GlcNAcs was much smaller [ 58 ].”
ResultChartrain, M. M., & Chu, L. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786367 · Cited by 108
“For example, glycans devoid of the bisecting fucose will confer the mAb a stronger interaction between the antibody and the NKC, resulting in higher ADCC mediated immune response [20-26].”
BackgroundIgG Fc Glycosylation in Human Immunity
Wang, T. T. (2019) · Current topics in microbiology and immunology · doi:10.1007/82_2019_152 · Cited by 99
Engineered affinity proteins for tumour‐targeting applications
Friedman, M., & Ståhl, S. (2009) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20080287 · Cited by 82
Rosati, S., van den Bremer, E. T., Schuurman, J., Parren, P. W., Kamerling, J. P., & Heck, A. J. (2013) · mAbs · doi:10.4161/mabs.26282 · Cited by 81
“To test the performance and demonstrate the versatility of the new analysis workflow, we selected three different samples: (1) a full-length (150 kDa), hinge deleted, IgG4 that exists in equilibrium with its half-antibody (75 kDa); (2) IgG4 mutants exhibiting highly complex glycosylation profiles; and (3) an IgG1 anti…”
MethodProtein Glycoengineering: An Approach for Improving Protein Properties
Ma, B., Guan, X., Li, Y., Shang, S., Li, J., & Tan, Z. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00622 · Cited by 91
“The high variability and controversial reliability of the results of protein glycoengineering based on bisecting GlcNAc was related to the previous lack of a clear and definite understanding of this type of glycosylation and how it is regulated (Shinkawa et al., 2003).”
BackgroundExpression and glycoengineering of functionally active heteromultimeric IgM in plants
Loos, A., Grünwald‐Gruber, C., Altmann, F., Mehofer, U., Hensel, F., Grandits, M., Oostenbrink, C., Stadlmayr, G., Furtmüller, P. G., & Steinkellner, H. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320544111 · Cited by 81
Maeda, E., Kita, S., Kinoshita, M., Urakami, K., Hayakawa, T., & Kakehi, K. (2012) · Analytical Chemistry · doi:10.1021/ac300234a · Cited by 82
Harnessing the potential of artificial neural networks for predicting protein glycosylation
Kotidis, P., & Kontoravdi, C. (2020) · Metabolic Engineering Communications · doi:10.1016/j.mec.2020.e00131 · Cited by 80
“…the N-linked oligosaccharide have been found to notably increase either the complement-dependent cytotoxicity (CDC) or the antibody-dependent cellular cytotoxicity (ADCC) activity of monoclonal antibody drugs (Shields et al., 2002; Shinkawa et al., 2003; Thomann et al., 2016; Houde et al., 2010).”
BackgroundHmiel, L. K., Brorson, K., & Boyne, M. T. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-8108-x · Cited by 92
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism
Braig, F., Kriegs, M., Voigtlaender, M., Habel, B., Grob, T. J., Biskup, K., Blanchard, V., Sack, M., Thalhammer, A., Batalla, I. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0754 · Cited by 87
Vanderven, H. A., Ana‐Sosa‐Batiz, F., Jegaskanda, S., Rockman, S. P., Laurie, K., Barr, I., Chen, W., Wines, B. D., Hogarth, P. M., Lambe, T., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.029 · Cited by 80
“This could be due to a number of factors including enhanced Ab avidity for its Ag or altered glycosylation of the IgG Fc region, which can change the binding affinity for Fc receptors (Ferrara et al., 2006; Ferrara et al., 2011; Shinkawa et al., 2003) and lead to altered immune effector functions like ADCC.”
Background3D Structure and Function of Glycosyltransferases Involved in N-glycan Maturation
Nagae, M., Yamaguchi, Y., Taniguchi, N., & Kizuka, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020437 · Cited by 82
“In terms of cancer treatment, removal of core fucose from therapeutic IgG drastically enhances (~100-fold) antibody-dependent cellular cytotoxicity (ADCC) [134,135], and this technique is now used clinically.”
MethodFc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
van der Horst, H. J., Nijhof, I. S., Mutis, T., & Chamuleau, M. E. D. (2020) · Cancers · doi:10.3390/cancers12103041 · Cited by 84
“The reported effects of hypergalactosylation on ADCC, however, range from completely absent to positive without addition of afucosylation [38,43,44] and positive with addition of afucosylation [45,46].”
BackgroundLiu, Z., Gunasekaran, K., Wang, W., Razinkov, V. I., Sekirov, L., Leng, E. C., Sweet, H., Foltz, I. N., Howard, M., Rousseau, A.-M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.513366 · Cited by 83
“The fucose attached to the N-linked glycan at Asn-297 of Fc sterically hinders the interaction of Fc with Fc RIIIA, and removal of fucose by glyco-engineering can increase the binding to Fc RIIIA, which translates into 50fold higher ADCC activity compared with wild type IgG1 controls (10, 11).”
BackgroundMultiplexed Analytical Glycomics: Rapid and Confident IgG N-Glycan Structural Elucidation
Mittermayr, S., Bones, J., Doherty, M., Guttman, A., & Rudd, P. M. (2011) · Journal of Proteome Research · doi:10.1021/pr200371s · Cited by 75
den Hoecke, S. V., Ehrhardt, K., Kolpe, A. B., Bakkouri, K. E., Deng, L., Grootaert, H., Schoonooghe, S., Smet, A., Bentahir, M., Roose, K., et al. (2017) · Journal of Virology · doi:10.1128/jvi.02500-16 · Cited by 77
Ha, T. K., Kim, D., Kim, C. L., Grav, L. M., & Lee, G. M. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107831 · Cited by 74
Glycoengineered antibodies: towards the next-generation of immunotherapeutics
Mastrangeli, R., Palinsky, W., & Bierau, H. (2018) · Glycobiology · doi:10.1093/glycob/cwy092 · Cited by 84
Glycosylation as a marker for inflammatory arthritis
Albrecht, S., Unwin, L., Muniyappa, M., & Rudd, P. M. (2014) · Cancer Biomarkers · doi:10.3233/cbm-130373 · Cited by 76
“Changes in IgG core-fucosylation may lead to an altered antibody-dependent cellular cytotoxicity (ADCC) [65,66].”
Mimoto, F., Igawa, T., Kuramochi, T., Katada, H., Kadono, S., Kamikawa, T., Shida-Kawazoe, M., & Hattori, K. (2013) · mAbs · doi:10.4161/mabs.23452 · Cited by 74
“Cytotoxicity of antibody against antigen X and antigen Y was measured using a standard 4-h (51)Cr release assay and calcein-AM release assay, respectively.(6,25,26) Peripheral blood mononuclear cells (PBMC) were purified from whole human blood of healthy donors and used as effector cells.”
BackgroundMethodBenralizumab in the treatment of severe asthma: design, development and potential place in therapy
Pelaia, C., Vatrella, A., Bruni, A., Terracciano, R., & Pelaia, G. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s155307 · Cited by 78
“52,53 In particular, benralizumab was generated in Chinese hamster ovary cells that lacked the enzyme α -1,6-fucosyltransferase.”
Colombo, M., Corsi, F., Foschi, D., Mazzantini, E., Mazzucchelli, S., Morasso, C., Occhipinti, E., Polito, L., Prosperi, D., Ronchi, S., et al. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.013 · Cited by 80
Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma
Ollila, T. A., Şahin, İ., & Olszewski, A. J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s165615 · Cited by 76
The importance of IgG glycosylation—What did we learn after analyzing over 100,000 individuals
Krištić, J., & Lauc, G. (2024) · Immunological Reviews · doi:10.1111/imr.13407 · Cited by 101
“78,88,89 On the other hand, the effect of bisecting GlcNAc on Fc γ RIIIa binding and ADCC in IgG antibodies with low levels of core fucosylation remains unclear.”
InfluentialLiu, S. D., Chalouni, C. M., Young, J. C., Junttila, T. T., Sliwkowski, M. X., & Lowe, J. B. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0125 · Cited by 80
Ihara, H., Ikeda, Y., & Taniguchi, N. (2005) · Glycobiology · doi:10.1093/glycob/cwj068 · Cited by 73
“Kinetic analyses and inhibition studies using derivatives of GDP- -L-fucose revealed that FUT8 catalyzes the reaction which depends on a rapid equilibrium random mechanism and strongly recognizes the base portion and diphosphoryl group of GDP- -L-fucose.”
BackgroundGlycosylation of IgG-Fc: a molecular perspective
Kiyoshi, M., Tsumoto, K., Ishii-Watabe, A., & Caaveiro, J. M. M. (2017) · International Immunology · doi:10.1093/intimm/dxx038 · Cited by 73
Aoyama, M., Hashii, N., Tsukimura, W., Osumi, K., Harazono, A., Tada, M., Kiyoshi, M., Matsuda, A., & Ishii‐Watabe, A. (2019) · mAbs · doi:10.1080/19420862.2019.1608143 · Cited by 79
Small-molecule control of antibody N-glycosylation in engineered mammalian cells
Chang, M. M., Gaidukov, L., Jung, G., Tseng, W. A., Scarcelli, J. J., Cornell, R. J., Marshall, J. K., Lyles, J. L., Sakorafas, P., Chu, A. A., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0288-4 · Cited by 79
Gu, J., Sato, Y., Kariya, Y., Isaji, T., Taniguchi, N., & Fukuda, T. (2008) · Journal of Proteome Research · doi:10.1021/pr800674g · Cited by 77
Hofmann, M., Große‐Hovest, L., Nuebling, T., Pyż, E., Bamberg, M., Aulwurm, S., Bühring, H.-J., Schwartz, K., Haen, S. P., Schilbach, K., et al. (2012) · Leukemia · doi:10.1038/leu.2011.372 · Cited by 72
Rosenberg, Y. J., Sack, M., Montefiori, D. C., Forthal, D. N., Mao, L., Hernandez-Abanto, S., Urban, L. A., Landucci, G., Fischer, R., & Jiang, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058724 · Cited by 72
Goldmacher, V. S., & Kovtun, Y. (2011) · Therapeutic Delivery · doi:10.4155/tde.10.98 · Cited by 79
Kiyoshi, M., Caaveiro, J. M. M., Tada, M., Tamura, H., Tanaka, T., Terao, Y., Morante, K., Harazono, A., Hashii, N., Shibata, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22199-8 · Cited by 77
Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid
Yehuda, S., & Padler-Karavani, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00021 · Cited by 71
“The absence of fucose residues enhances antibody-dependent cellular cytotoxicity (31).”
BackgroundRozan, C., Cornillon, A., Pétiard, C., Chartier, M., Béhar, G., Boix, C., Kerfélec, B., Robert, B., Pèlegrin, A., Chames, P., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1012 · Cited by 81
“SDS-PAGE andWestern blot analyses showed the absence of breakdown products of both bsFabs (data not shown), further confirming that Jurkat-huFcγRIIIa/γ bsFab (nmol/L) 100330 113.71.2 MC38-CEA N u m b er o f ce lls Fluorescence intensity N u m b er o f ce lls Fluorescence intensity MC38-CEA + Jurkat-huFcγRIIIa/γ MC38-C…”
BackgroundInfluentialGlycoengineering in CHO cells: advances in systems biology
Tejwani, V., Andersen, M. R., Nam, J. H., & Sharfstein, S. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700234 · Cited by 70
Ishida, T., Utsunomiya, A., Jo, T., Yamamoto, K., Kato, K., Yoshida, S., Takemoto, S., Suzushima, H., Kobayashi, Y., Imaizumi, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13343 · Cited by 71
Kizuka, Y., Nakano, M., Yamaguchi, Y., Nakajima, K., Oka, R., Sato, K., Ren, C., Hsu, T.-L., Wong, C., & Taniguchi, N. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.023 · Cited by 73
Selection, design, and engineering of therapeutic antibodies
Presta, L. G. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.08.003 · Cited by 72
Catenacci, D. V. T., Tesfaye, A. A., Tejani, M. A., Cheung, E. M., Eisenberg, P. D., Scott, A. J., Eng, C., Hnatyszyn, J. H., Marina, N. M., Powers, J. M., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0141 · Cited by 71
Nam, J. H., Zhang, F., Ermonval, M., Linhardt, R. J., & Sharfstein, S. T. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21853 · Cited by 69
“…CHO cell line (Shields et al., 2002) or produced in rat hybridoma cells and fractionated by lectin affinity chromatography for reduced fucosylation (Shinkawa et al., 2003) exhibited up to 50-fold increased affinity to human FcgRIIIA and increased antibody-dependent cellular cytotoxicity (ADCC).”
BackgroundN-glycan alterations are associated with drug resistance in human hepatocellular carcinoma
Kudo, T., Nakagawa, H., Takahashi, M., Hamaguchi, J., Kamiyama, N., Yokoo, H., Nakanishi, K., Nakagawa, T., Kamiyama, T., Deguchi, K., et al. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-32 · Cited by 75
“Alterations in core fucosylation are associated with changes in protein function: fucose removal from oligosaccharides of the scFv-Fc domain of human IgG1 results in significantly enhanced cellular cytotoxicity [ 13- 15 ].”
BackgroundNwosu, C. C., Yau, H. K., & Becht, S. (2015) · Analytical Chemistry · doi:10.1021/ac5040743 · Cited by 70
Mantovani, S., Oliviero, B., Varchetta, S., Mele, D., & Mondelli, M. U. (2020) · Cancers · doi:10.3390/cancers12040926 · Cited by 72
Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions
Kellner, C., Derer, S., Valerius, T., & Peipp, M. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.036 · Cited by 85
Plasma protein N-glycan signatures of type 2 diabetes
Dotz, V., Lemmers, R. F. H., Reiding, K. R., Ederveen, A. L. H., Lieverse, A. G., Mulder, M. T., Sijbrands, E. J. G., Wuhrer, M., & van Hoek, M. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.08.005 · Cited by 71
“In contrast, IgG-related galactosylation (A2FS0G) tended to decrease in diabetes, which is in line with our study on IgG [19].”
BackgroundInfluentialPerspectives for Glyco-Engineering of Recombinant Biopharmaceuticals from Microalgae
Barolo, L., Abbriano, R. M., Commault, A. S., George, J., Kahlke, T., Fabris, M., Padula, M. P., Lopez, A., Ralph, P. J., & Pernice, M. (2020) · Cells · doi:10.3390/cells9030633 · Cited by 73
Hirata, T., & Kizuka, Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-70115-4_1 · Cited by 88
Dufva, O., Gandolfi, S., Huuhtanen, J., Dashevsky, O., Duàn, H., Saeed, K., Klievink, J., Nygren, P. J., Bouhlal, J., Lahtela, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.008 · Cited by 88
Chan, K. F., Shahreel, W., Wan, C., Teo, G., Hayati, N., Tay, S. J., Tong, W. H., Yang, Y., Rudd, P. M., Zhang, P., et al. (2016) · Biotechnology Journal · doi:10.1002/biot.201500331 · Cited by 68
“It is now widely recognized that removal of core fucose from the N-glycans of human IgG1 antibody significantly enhances its affinity towards FcγRIIIa, and therefore dramatically improves its ADCC activity [4, 5].”
BackgroundAnalyzing Antibody–Fc-Receptor Interactions
Nimmerjahn, F., & Ravetch, J. V. (2008) · Innate Immunity · doi:10.1007/978-1-59745-570-1_9 · Cited by 68
Majewska, N. I., Tejada, M. L., Betenbaugh, M. J., & Agarwal, N. (2020) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-102419-010001 · Cited by 81
“(23) used human peripheral blood mononuclear cells to demonstrate that the increased ADCC of an anti-CD20 antibody was associated with low fucose (9%) and not the presence of bisecting GlcNAc or galactose.”
MethodBraza, M. S., Klein, B., Fiol, G., & Rossi, J. (2010) · Haematologica · doi:10.3324/haematol.2010.029520 · Cited by 75
The Significance of Glycosylation Analysis in Development of Biopharmaceuticals
Kawasaki, N., Itoh, S., Hashii, N., Takakura, D., Qin, Y., Huang, X., & Yamaguchi, T. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.796 · Cited by 67
Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG
Rose, R. J., van Berkel, P. H. C., van den Bremer, E. T. J., Labrijn, A. F., Vink, T., Schuurman, J., Heck, A. J. R., & Parren, P. W. H. I. (2013) · mAbs · doi:10.4161/mabs.23532 · Cited by 67
Immunopathogenesis of lymphoma: Focus on CCR4
Ishida, T., & Ueda, R. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2010.01767.x · Cited by 66
Wang, H., Xu, Q., Zhao, C., Zhu, Z., Zhu, X., Zhou, J., Zhang, S.-M., Yang, T., Zhang, B., Li, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000661 · Cited by 67
Prater, B. D., Connelly, H. M., Qin, Q., & Cockrill, S. L. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.10.023 · Cited by 70
The association between galactosylation of immunoglobulin G and body mass index
Perković, M. N., Pučić‐Baković, M., Krištić, J., Novokmet, M., Huffman, J. E., Vitart, V., Hayward, C., Rudan, I., Wilson, J. F., Campbell, H. J., et al. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.08.014 · Cited by 74
“…of oligosaccharides, are important for structural integrity of IgGmolecules and they play a crucial role in activation of complement (Malhotra et al., 1995), in interactions with Fc receptors (Adler et al., 1995) and in antibody-dependent cell mediated cytotoxicity (Shinkawa et al., 2003).”
Isolation and characterization of IgG1 with asymmetrical Fc glycosylation
Ha, S., Ou, Y., Vlasak, J., Li, Y., Wang, S., Vo, K., Du, Y., Mach, A., Fang, Y., & Zhang, N. (2011) · Glycobiology · doi:10.1093/glycob/cwr047 · Cited by 66
Rouwendal, G., Wuhrer, M., Florack, D. E. A., Koeleman, C. A. M., Deelder, A. M., Bakker, H., Stoopen, G. M., van Die, I., Helsper, J. P. F. G., Hokke, C. H., et al. (2006) · Glycobiology · doi:10.1093/glycob/cwl078 · Cited by 72
“In the N-glycosylation pathway, the action of GnT-III is preceded by GnT-I with GlcNAcMan5GlcNAc2 and GlcNAc2Man3GlcNAc2 constituting the primary acceptors, whereas GlcNAcMan3GlcNAc2 is a relatively poor acceptor (Harpaz and Schachter 1980a; Narasimhan 1982; Schachter et al. 1983; Allen et al. 1984).”
BackgroundIto, A., Ishida, T., Utsunomiya, A., Sato, F., Mori, F., Yano, H., Inagaki, A., Suzuki, S., Takino, H., Ri, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900699 · Cited by 67
“likely due to the defucosylation (4, 9, 19) of the therapeutic Ab.”
BackgroundAnalysis ofN-glycan in serum glycoproteins fromdb/dbmice and humans with type 2 diabetes
Itoh, N., Sakaue, S., Nakagawa, H., Kurogochi, M., Ohira, H., Deguchi, K., Nishimura, S., & Nishimura, M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00182.2007 · Cited by 72
“1,6-Fucosylation regulates E-cadherin-mediated cell adhesion (13), 3 1 integrin function (47), antibody-dependent cellular cytotoxicity of IgG (38, 39), liver lysosomal acid lipase activity (43), transforming growth factor- 1 signaling (45), EGF receptor-mediated intracellular signaling (44), and protein secretion fro…”
BackgroundOgata, S., Shimizu, C., Franco, A., Touma, R., Kanegaye, J. T., Choudhury, B. P., Naidu, N. N., Kanda, Y., Hoang, L. T., Hibberd, M. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081448 · Cited by 66
“The role of fucose in immune regulation is demonstrated by the 100-fold increase in affinity of the activating FcγRIIIA on NK cells and IIIb on neutrophils for all classes of human IgG following removal of the core fucose residue from the N-glycan in the IgG Fc region [43,51-53].”
BackgroundSelf-citationPhase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Aftimos, P. G., Rolfo, C. D., Rottey, S., Offner, F. C., Bron, D., Maerevoet, M., Soria, J., Moshir, M., Dreier, T., Rompaey, L. V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0613 · Cited by 69
“It has been modified by afucosylation of the Fc region to induce enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) using POTELLIGENT® technology (24,25), to provide a potent mAb for use in cancer therapy.”
MethodBiological Therapies in the Treatment of Cancer—Update and New Directions
Papiez, M. A., & Krzyściak, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111694 · Cited by 81
Edwards, E., Livanos, M., Krueger, A., Dell, A., Haslam, S. M., Smales, C. M., & Bracewell, D. G. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28066 · Cited by 80
“This was achieved by disrupting both FUT8 alleles using sequential homologous recombination (Shinkawa et al., 2003).”
BackgroundMethodThe emerging importance of α-L-fucose in human breast cancer: a review.
Listinsky, J. J., Siegal, G. P., & Listinsky, C. M. (2011) · PubMed Central · Cited by 79
Gasdaska, J. R., Sherwood, S. W., Regan, J. T., & Dickey, L. F. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.01.001 · Cited by 75
Activating and inhibitory FcγRs in autoimmune disorders
Nimmerjahn, F. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0052-1 · Cited by 76
Serna, S., Yan, S., Martín‐Lomas, M., Wilson, I. B. H., & Reichardt, N. (2011) · Journal of the American Chemical Society · doi:10.1021/ja205392z · Cited by 69
Natsume, A., Wakitani, M., Yamane‐Ohnuki, N., Shoji-Hosaka, E., Niwa, R., Uchida, K., Satoh, M., & Shitara, K. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.07.025 · Cited by 74
Self-citationNew paradigms for functional HIV-specific nonneutralizing antibodies
Forthal, D. N., Hope, T. J., & Alter, G. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328363d486 · Cited by 70
Obinutuzumab in hematologic malignancies: Lessons learned to date
Illidge, T., Klein, C., Sehn, L. H., Davies, A. J., Salles, G. A., & Cartron, G. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.07.003 · Cited by 70
Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies
Ishii‐Watabe, A., & Kuwabara, T. (2018) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2018.11.004 · Cited by 73
Glycosylation profiles of therapeutic antibody pharmaceuticals
Wacker, C., Berger, C. N., Girard, P., & Meier, R. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.06.010 · Cited by 69
“glycoforms have been clearly shown to increase binding to Fcc RIIIa receptors [17,26].”
BackgroundStable-isotope-assisted NMR approaches to glycoproteins using immunoglobulin G as a model system
Kato, K., Yamaguchi, Y., & Arata, Y. (2010) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2010.03.001 · Cited by 66
Made in Academia: The Effect of Institutional Origin on Inventors’ Attention to Science
Bikard, M. A. (2018) · Organization Science · doi:10.1287/orsc.2018.1206 · Cited by 72
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Cuesta-Mateos, C., Alcaraz-Serna, A., Somovilla-Crespo, B., & Muñoz-Calleja, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01936 · Cited by 63
“Nevertheless, its Fc was selectively defucosylated to reach a potent ADCC via high-affinity binding to the FcγRIIIa on effector cells (215, 217).”
Background
Metadata
- Authors
- Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., & Shitara, K.
- Affiliations
- Kyowa Kirin (Japan) (JP)
- Corresponding author
- Shitara, Kenya
- ORCID
- Uchida, Kazuhisa
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 5
- Pages
- 3466-3473
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2084136419
- Cited by
- 1,413
- References
- 33
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 55 · 2023: 45 · 2022: 77 · 2021: 78 · 2020: 87 · 2019: 70 · 2018: 83 · 2017: 77 · 2016: 71 · 2015: 72 · 2014: 78 · 2013: 56 · 2012: 67
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6498 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- antibody-dependent cellular cytotoxicity, fucosylation, bisecting N-acetylglucosamine, galactose, FUT8, alpha-1,6-fucosyltransferase, humanized monoclonal antibody, CHO cell expression, antibody glycosylation, therapeutic antibodies
- MeSH terms
- Acetylglucosamine, Animals, Antibody-Dependent Cell Cytotoxicity, Base Sequence, Carbohydrate Conformation, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Fucose, Galactose, Cricetinae, Humans, Immunoglobulin G, Molecular Sequence Data, Oligosaccharides, Recombinant Fusion Proteins, Transfection, Polymerase Chain Reaction, CHO Cells, DNA Primers, Lectins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.